000189603 001__ 189603
000189603 005__ 20180913062103.0
000189603 0247_ $$2doi$$a10.1155/2013/521231
000189603 022__ $$a1740-2522
000189603 02470 $$2ISI$$a000321640100001
000189603 037__ $$aARTICLE
000189603 245__ $$aPeptide-Based Vaccinology: Experimental and Computational Approaches to Target Hypervariable Viruses through the Fine Characterization of Protective Epitopes Recognized by Monoclonal Antibodies and the Identification of T-Cell-Activating Peptides
000189603 260__ $$bHindawi Publishing Corporation$$c2013$$aNew York
000189603 269__ $$a2013
000189603 300__ $$a12
000189603 336__ $$aReviews
000189603 520__ $$aDefining immunogenic domains of viral proteins capable of eliciting a protective immune response is crucial in the development of novel epitope-based prophylactic strategies. This is particularly important for the selective targeting of conserved regions shared among hypervariable viruses. Studying postinfection and postimmunization sera, as well as cloning and characterization of monoclonal antibodies (mAbs), still represents the best approach to identify protective epitopes. In particular, a protective mAb directed against conserved regions can play a key role in immunogen design and in human therapy as well. Experimental approaches aiming to characterize protective mAb epitopes or to identify T-cell-activating peptides are often burdened by technical limitations and can require long time to be correctly addressed. Thus, in the last decade many epitope predictive algorithms have been developed. These algorithms are continually evolving, and their use to address the empirical research is widely increasing. Here, we review several strategies based on experimental techniques alone or addressed by in silico analysis that are frequently used to predict immunogens to be included in novel epitope-based vaccine approaches. We will list the main strategies aiming to design a new vaccine preparation conferring the protection of a neutralizing mAb combined with an effective cell-mediated response.
000189603 700__ $$uUniv Vita Salute San Raffaele, Inst Microbiol & Virol, I-20132 Milan, Italy$$aCastelli, Matteo
000189603 700__ $$uUniv Vita Salute San Raffaele, Inst Microbiol & Virol, I-20132 Milan, Italy$$aCappelletti, Francesca
000189603 700__ $$uUniv Vita Salute San Raffaele, Inst Microbiol & Virol, I-20132 Milan, Italy$$aDiotti, Roberta Antonia
000189603 700__ $$uUniv Vita Salute San Raffaele, Inst Microbiol & Virol, I-20132 Milan, Italy$$aSautto, Giuseppe
000189603 700__ $$uUniv Vita Salute San Raffaele, Inst Microbiol & Virol, I-20132 Milan, Italy$$aCriscuolo, Elena
000189603 700__ $$0243887$$g182443$$aDal Peraro, Matteo
000189603 700__ $$uUniv Vita Salute San Raffaele, Inst Microbiol & Virol, I-20132 Milan, Italy$$aClementi, Nicola
000189603 773__ $$tClinical & Developmental Immunology
000189603 909C0 $$xU11830$$0252070$$pUPDALPE
000189603 909CO $$pSV$$preview$$ooai:infoscience.tind.io:189603
000189603 937__ $$aEPFL-REVIEW-189603
000189603 973__ $$rREVIEWED$$sPUBLISHED$$aEPFL
000189603 980__ $$aREVIEW